Global Dengue Vaccine Market is valued at USD 325.4 Million in 2021 and is expected to reach USD 964.9 Million by 2028 with a CAGR of 16.8% over the forecast period.
Global Dengue Vaccine Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2021-2028- Increasing incidences of dengue fever, rising clinical trials of dengue vaccines, and rising number of government initiatives controlling the dengue outbreak are major factors anticipated to drive the growth of The Global Dengue Vaccines Market.
Dengue vaccine is gives protection against dengue fever in humans. The vaccine for dengue has been difficult task as it has 4 variants and each of the variant has seen in particular season. The mosquito Aedes species mosquito spread dengue viruses to humans through the bite. Dengue is caused by one of any of four related viruses are dengue virus 1, 2, 3, 4. Dengue can become serious as platelets were reduced in the infection and it can be deadly sometimes. There is no remedy for dengue, and treatment has been given as per the symptoms. Thus, vaccination is the preventive measure taken against dengue. The dengue vaccine development has been started since 1920s. However, the successful dengue vaccine has been developed in 2021.
The Covid-19 pandemic has also impacted on the global dengue vaccine market. The Covid-19 vaccine development has been given the priority by healthcare industry and the vaccination of dengue has been slowed down. The supply chain disruptions and restrictions on research and development of dengue vaccine due to the lack of raw material hamper the market during the Covid-19 pandemic.
The global dengue vaccine market is segmented into on the basis of type, application, and region & country level. On the basis of type, the global dengue vaccine market is segmented into CYD-TDV, Tak-003, and others. On the basis of application, the market is segmented into hospitals, government institutes, non-governmental organizations (NGOs), and others.
Some of the key players for global dengue vaccine market are
On November 5th, 2019; Takeda Pharmaceutical Company Limited announced the starting of its innovative manufacturing plant in Singen, Germany, for its dengue vaccine candidate known as TAK-003. The Singen vaccine plant will be utilized for formulation, fill, finish and secondary packaging of the dengue vaccine candidate starting with the packaging line. Takeda invested more than 130 million Euro and will employ up to 200 employees in the vaccine plant.
On September 17th, 2019; Indian Council of Medical Research (ICMR) launched dengue vaccine to fight with the dengue outbreak. The dengue serotype survey has been taken to identify prevalence of disease. The vaccine has been given to areas which has shown highest amount of dengue patients.
On August 20th, 2018; Serum Institute of India prepared to launch its new vaccine against dengue in South America in next year. The company haven’t revealed vaccines scientific details. However, they started registrations for the vaccine.
One of the major factors driving the growth of the global dengue vaccines market is increasing incidences of dengue fever. To prevent the dengue, vaccine is vital solution which raises the demand of dengue vaccines. For instance; according to the World Health Organization (WHO); dengue is the fastest spreading mosquito-borne viral disease, which is estimated to cause approximately 390 million infections and 20,000 deaths globally each year. In addition, rising number of clinical trials of dengue vaccines is also fuelling the market growth. For instance; as per the news published on April 20th, 2018; clinical trials of dengue vaccines for five additional dengue vaccine candidates are in clinical development, with two candidates which are developed by NIH/Butantan and Takeda now in Phase III trials. These conclusive results in the future provide entry of potential vaccine candidate may foster the market growth.
Furthermore, growing investment in the research and development activities for developing dengue vaccines is also supplementing the growth of global dengue vaccines market. For example; on September 29th, 2021; the National Centre for Biological Sciences (NCBS) scientists has collaborated with CBS scientists and developed a Dengue DNA vaccine candidate. The dengue vaccine development has been game changer and it was also very cheap. Furthermore, growing number of supportive government initiatives for controlling the dengue outbreak are also augumenting the market growth.
However, high risk associated with dengue vaccines may hamper the growth of the global dengue vaccines market. In spite of that, increasing research and development in this field can provide various opportunities for the further growth of the global dengue vaccines market.
Asia Pacific is expected to witness a fastest growth in the global dengue vaccine market due to rising prevalence of dengue, increasing demand for vaccines and growing adoption of dengue vaccines and government awareness programmes in this region. For instance; according to World Health Organization for the period of 2019-2024 dengue is one of the top ten diseases. Also, increasing demand of vaccines in Asia pacific region for controlling disease is also supplementing the market growth in this region. For instance; according to International Vaccine Institute; South Korea, from 2015-2022 vaccination schedule for routine vaccination against dengue around 7.8–62.9 million doses of dengue vaccine are needed. Moreover, on October 7th, 2021, Takeda’s TAK-003 vaccine is in the process of approval for use in India which has been shown to prevent hospitalizations in 83.6% of trial participants and 62% reduction in dengue illness. This approval will further acerate the growth of the dengue vaccines in Asia Pacific region.
North America is expected to show a significant growth in the global dengue vaccine market due to the highly developed healthcare infrastructure, and high awareness about dengue vaccines in this region. For instance; in May 2019, Food & Drug Administration (FDA) granted permission for the use of Sanofi’s Dengvaxia which is live attenuated vaccine for 9–16-year-old children. Additionally, North America’s highly developed healthcare infrastructure also providing growth to the global dengue vaccines market within the forecast period.
|Historical data||2015 - 2020|
|Forecast Period||2021 - 2028|
|Market Size in 2021:||USD 325.4 Million|
|Base year considered||2020|
|Forecast Period CAGR %:||
|Market Size Expected in 2028:||USD 964.9 Million|
|Tables, Charts & Figures:||175|
|Dengue Vaccines Companies||Glaxo Smith Kline, Merck Sharp & Dohme, Sanofi, Takeda Pharmaceuticals, Panacea, GeneOne Life Sciences Inc., Medigen Biologics, Panacea Biotec, Sun Pharmaceutical. U.S NIH, Vabiotec, others.|
|Segments Covered||By Type, By Application|
|Regional Analysis||North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa|
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us email@example.comJOIN US
BrandEssence® Market Research and Consulting Pvt ltd.
124, City Road, London EC1V 2NX
© Copyright 2023-24 BrandEssence® Market Research and Consulting Pvt ltd. All Rights Reserved | Designed by BrandEssence®